179 related items for PubMed ID: 23564929
1. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
Brogan P, Levin M.
Evid Based Med; 2013 Dec; 18(6):217-8. PubMed ID: 23564929
[No Abstract] [Full Text] [Related]
2. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S, Dong Y, Yin Y, Krucoff MW.
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[Abstract] [Full Text] [Related]
3. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
Chandelia S.
Cardiol Young; 2015 Aug; 25(6):1228. PubMed ID: 25904322
[No Abstract] [Full Text] [Related]
4. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW.
JAMA Pediatr; 2016 Dec 01; 170(12):1156-1163. PubMed ID: 27749951
[Abstract] [Full Text] [Related]
5. Treatment of Kawasaki disease: corticosteroids revisited.
Newburger JW.
J Pediatr; 1999 Oct 01; 135(4):411-3. PubMed ID: 10518072
[No Abstract] [Full Text] [Related]
6. Is there a role for corticosteroids in Kawasaki disease?
Shulman ST.
J Pediatr; 2003 Jun 01; 142(6):601-3. PubMed ID: 12838185
[No Abstract] [Full Text] [Related]
7. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
Yang X, Liu G, Huang Y, Chen S, Du J, Jin H.
Cardiol Young; 2015 Aug 01; 25(6):1182-90. PubMed ID: 25597708
[Abstract] [Full Text] [Related]
8. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
[Abstract] [Full Text] [Related]
9. Response of refractory Kawasaki disease to intravenous methylprednisolone.
Shah I, Prabhu SS.
Ann Trop Paediatr; 2009 Mar 28; 29(1):51-3. PubMed ID: 19222935
[Abstract] [Full Text] [Related]
10. [Reply to questions regarding diagnosis and treatment of Kawasaki disease].
Wang HW.
Zhonghua Er Ke Za Zhi; 2006 May 28; 44(5):337-8. PubMed ID: 16780708
[No Abstract] [Full Text] [Related]
11. [Advance in diagnosis and treatment of intravenous immunogolobulin-resistant Kawasaki disease].
Zhang Q.
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr 28; 11(4):318-21. PubMed ID: 19374823
[No Abstract] [Full Text] [Related]
12. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
Kobayashi T, Inoue Y, Morikawa A.
Nihon Rinsho; 2008 Feb 28; 66(2):332-7. PubMed ID: 18260333
[Abstract] [Full Text] [Related]
13. Kawasaki disease: part II. Complications and treatment.
Bayers S, Shulman ST, Paller AS.
J Am Acad Dermatol; 2013 Oct 28; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
[Abstract] [Full Text] [Related]
14. Evaluation of clinical characteristics of Kawasaki syndrome and risk factors for coronary artery abnormalities among children in Denmark.
Patel A, Holman RC, Callinan LS, Sreenivasan N, Schonberger LB, Fischer TK, Belay ED.
Acta Paediatr; 2013 Apr 28; 102(4):385-90. PubMed ID: 23278838
[Abstract] [Full Text] [Related]
15. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May 28; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
16. Resistant Kawasaki disease.
Nachiappan J, May M, Hawker RE, Hong P.
J Paediatr Child Health; 2004 May 28; 40(9-10):576-8. PubMed ID: 15367156
[No Abstract] [Full Text] [Related]
17. [Improving the diagnosis and therapy of Kawasaki disease].
Du JB.
Zhonghua Er Ke Za Zhi; 2006 May 28; 44(5):321-3. PubMed ID: 16780704
[No Abstract] [Full Text] [Related]
18. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ, Lin MT, Lu CY, Chen JM, Lee PI, Huang LM, Wu MH, Chang LY.
J Microbiol Immunol Infect; 2018 Jun 28; 51(3):321-331. PubMed ID: 28927685
[Abstract] [Full Text] [Related]
19. Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial.
Etoom Y, Banihani R, Finkelstein Y.
J Popul Ther Clin Pharmacol; 2013 Jun 28; 20(2):e91-4. PubMed ID: 23648367
[No Abstract] [Full Text] [Related]
20. The use of corticosteroid therapy in refractory Kawasaki patients.
Al-Mayouf SM.
Clin Rheumatol; 2004 Feb 28; 23(1):11-3. PubMed ID: 14749974
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
